Medical Condition

glioblastoma multiforme

Total Trials

11

Recruiting Now

11

Trial Phases

Phase 1, EARLY_Phase 1, Phase 3

ClinicalMetric tracks all active clinical trials for glioblastoma multiforme sourced from ClinicalTrials.gov. Each listing includes the NCT identifier, current recruitment status, phase, primary endpoints, sponsor, estimated enrollment, and participating countries — updated daily as new studies open and status changes.

Recruiting trials currently enrolling participants, with eligibility criteria and age requirements
Phase 1–4 studies from early safety trials to post-marketing surveillance
NIH, pharmaceutical sponsor, and academic medical center studies worldwide
AI-powered plain-language summary available for every trial listing

Frequently Asked Questions — glioblastoma multiforme Clinical Trials

How many clinical trials are currently recruiting for glioblastoma multiforme?

ClinicalMetric currently tracks 11 actively recruiting clinical trials for glioblastoma multiforme, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 11. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.

What trial phases are available for glioblastoma multiforme?

glioblastoma multiforme research spans Phase 1 (3 trials), Phase 2 (2 trials), Phase 3 (1 trial). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.

How do I find out if I qualify for a glioblastoma multiforme clinical trial?

Eligibility criteria for glioblastoma multiforme trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.

Trial Phases

Phase 1

Phase 2

Phase 3

Enrollment

564 pts

Location

United States, Belgi...

Sponsor

Jasper Gerritsen

View Trial →

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: April 2026 · Data Methodology

glioblastoma multiforme

Frequently Asked Questions — glioblastoma multiforme Clinical Trials

Recruiting Clinical Trials

Neoadjuvant Radio-chemotherapy Safety Pilot Study in Patients With Glioblastoma

The PALSUR-study: Palliative Care Versus Surgery in High-grade Glioma Patients (ENCRAM 2203)

The RECSUR-study: Resection Versus Best Oncological Treatment for Recurrent Glioblastoma (ENCRAM 2302)

Targeted Pediatric High-Grade Glioma Therapy

Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion

Sonodynamic Therapy in Patients With Recurrent GBM

Repeated Superselective Intraarterial Cerebral Infusion (SIACI) of Bevacizumab With Temozolomide and Radiation Compared to Temozolomide and Radiation Alone in Newly Diagnosed GBM

Loupe-Based Intraoperative Fluorescence Imaging

APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors

Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant

The RESBIOP-study: Resection Versus Biopsy in High-grade Glioma Patients (ENCRAM 2202)